The AI Boom’s Next Winners May Have Nothing to Do With Nvidia

The AI Boom’s Next Winners May Have Nothing to Do With Nvidia

Business man looking through binoculars

Source: iStock

Listen to the audio version of this article (generated by AI).

Editor’s Note: I’ve been telling you that the AI Revolution is far from over. And as we discussed yesterday, NVIDIA’s spectacular earnings certainly reinforced that.

But NVIDIA isn’t the only company benefiting from the AI boom.

In fact, my colleague Eric Fry believes some of the biggest opportunities ahead could come from companies that are putting artificial intelligence to work, rather than simply building the infrastructure behind it.

And I think he’s onto something.

That’s why I wanted to share his latest research with you today.

Eric has identified some remarkable developments in healthcare, where AI is already helping doctors diagnose diseases, hospitals operate more efficiently and pharmaceutical companies develop new treatments.

He’s also found a beaten-down pharmaceutical stock that he believes Wall Street has overlooked.

Now, Eric believes these developments are part of something much bigger. In fact, he’s identified an important shift in the AI economy that could change where investors find the next generation of winners.

And he’s going to explain it all in a special presentation called Life After Nvidia, premiering Monday, November 23, at 10 a.m. Eastern.

I encourage you to reserve your free spot for Eric’s presentation right here.

He’ll explain why he believes the AI Revolution is entering a new phase, where the next big opportunities could emerge and share an AI stock recommendation with everyone who watches.

I encourage you to take a few minutes to register today. And be sure to read Eric’s essay below. I think you’ll find his research fascinating.

Here’s Eric…

*************************

Nvidia Corp. (NVDA) has accomplished something that very few companies ever do – make a $116 billion quarter almost meaningless.

The chipmaker reported Tuesday night that its quarterly revenue had more than doubled from a year earlier. It expects another $130 billion in sales next quarter.

Its business is booming.

Wall Street was more focused on former CEO Jensen Huang who resigned after 33 years at the helm. His departure followed a personal scandal with national security implications.

But there is a more important story many investors are missing – one that could prove very expensive.

In 2000, Cisco Systems Inc. (CSCO) was delivering one impressive quarter after another. Its equipment was essential to the internet boom, and demand seemed almost limitless. Not unlike Nvidia now.

But I wasn’t buying the excitement. In fact, I’d urged investors to sell Cisco – even as Wall Street remained enamored with the stock. Cisco went on to lose roughly three-quarters of its value in the subsequent collapse.

I’m not predicting the same fate for Nvidia. But I’ve seen firsthand how a great company can become a terrible investment when investors lose sight of what they’re paying for it.

That’s why I’m looking beyond Nvidia’s latest earnings at what happens after those chips are sold – and who profits from putting them to work.

Artificial intelligence is helping doctors detect heart attacks. It’s identifying promising new drugs for diseases that have resisted treatment for decades. It’s helping hospitals make better use of their beds, equipment, and staff.

And much of this is happening at companies that Wall Street continues to treat like yesterday’s news.

I believe this is where some of the most compelling opportunities of the AI Revolution are beginning to emerge. In fact, I’ll show you one beaten-down pharmaceutical stock that I believe Wall Street has badly mispriced – and why AI could help revive its fortunes.

Let’s take a look.

The AI Revolution Moves Into the Hospital

Consider Insilico Medicine Cayman TopCo (ISLMF), which is developing an experimental IPF drug called Rentosertib to treat a serious lung disease that causes progressive scarring.

AI helped Insilico researchers identify the biological target associated with the disease. Then it helped design a molecule that might treat it.

Earlier clinical trials produced encouraging improvements in lung function among patients receiving the highest dose, compared with patients taking a placebo. The drug has advanced into Phase III testing.

Rentosertib may never win approval. But AI has already helped researchers identify a promising treatment and move it into advanced human testing. That’s a potentially enormous breakthrough for an industry where failure is the rule, not the exception.

And it’s hardly an isolated example.

Consider a system called Queen of Hearts. The U.S. Food and Drug Administration has authorized this AI-powered technology to help doctors detect heart attacks using an ordinary electrocardiogram, or ECG.

In a clinical evaluation, the system identified 92% of confirmed heart attacks on the first ECG, compared with 71% under standard care.

In an emergency room, the difference between catching a heart attack and missing one can be a matter of life and death. An AI system that helps identify more of those cases sooner could improve treatment decisions and reduce costly complications.

Then there’s the less glamorous side of healthcare.

GE HealthCare Technologies Inc. (GEHC) has developed software that can anticipate hospital capacity problems up to 72 hours in advance. It helps administrators determine which patient transfers and discharges need attention before a shortage of available beds becomes a crisis.

Nobody is going to make a Hollywood movie about hospital bed management. But a hospital that can treat more patients with the same facilities has a pretty good reason to invest in the technology.

Drug development offers an even bigger opportunity. Bringing a new medicine to market can take more than a decade and cost billions of dollars. And most experimental drugs fail along the way.

Anything that helps researchers find promising treatments faster – or abandon bad candidates earlier – could be worth a fortune.

Stanford-led researchers recently demonstrated the scale of this possibility. They assembled a virtual biotech research effort involving approximately 37,000 AI agents. Those agents analyzed nearly 56,000 clinical trials, searching for patterns that could help predict which experimental drugs were most likely to succeed.

That’s 37,000 researchers who don’t need salaries, vacations, or company-sponsored dental plans. That’s an interesting business model.

Of course, AI can’t replace clinical trials or guarantee a drug’s success. But if AI helps a pharmaceutical company identify a promising drug in half the time, or abandon a doomed candidate two years earlier, the financial benefits could be enormous.

This is the distinction between what I call the AI Builders and the AI Appliers. The Builders are spending hundreds of billions of dollars creating the infrastructure. The Appliers are using that infrastructure to make existing businesses more profitable.

Unlike the Builders, they don’t need to construct a $20 billion data center to get started.

And that brings me to a pharmaceutical company Wall Street seems to have given up on.

The Obesity-Drug Giant Wall Street Left Behind

I’m talking about Novo Nordisk A/S (NVO), the Danish pharmaceutical giant that’s been getting its clock cleaned by rival Eli Lilly and Co. (LLY) in the obesity-drug market.

Lilly has captured a substantial share of the injectable-drug market. Novo, meanwhile, has suffered clinical disappointments, pricing pressure, and a bruising stock-market decline.

But Wall Street may be declaring victory for Lilly a little too soon.

The next battleground is obesity pills, and there Novo has an early advantage. Its oral version of Wegovy captured nearly 90% of the early U.S. market for oral obesity treatments, according to the figures I examined in September.

Lilly won the shot… but Novo is winning the pill.

Plus, Novo is already putting AI to work. The company has established collaborations involving Microsoft, Valo Health, OpenAI, and Amazon Web Services to improve drug research and business operations.

At a September presentation to investors, Novo described how AI helped researchers evaluate approximately 2,000 molecules while cutting the time needed to identify a drug candidate by 50%.

That’s a meaningful improvement in an expensive business. And it’s happening at an established, profitable company rather than a speculative startup hoping someday to turn a profit.

When I first recommended Novo in September, its shares traded at roughly 14 times earnings, compared with approximately 34 times for Lilly.

Novo still faces serious competition, pricing pressure, and uncertain sales growth. But those problems are hardly secrets. I believe the market has already punished the stock more than those challenges justify.

Investors don’t need Novo to become the next Nvidia. They just need this profitable drugmaker to be worth more than Wall Street currently thinks it is.

Life After Nvidia

Nvidia’s latest earnings were extraordinary. But they tell us how much money the company is making selling AI infrastructure – not who will ultimately make the most money using it.

During the internet boom, the companies that built the networks weren’t necessarily the ones that captured the greatest rewards. I suspect we’re approaching a similar divide in AI.

And healthcare is just one place to look.

In my upcoming Life After Nvidia presentation (save your spot here), I’ll explain why I believe the AI investment landscape is approaching a significant turning point — a “Crossing” that could separate the companies still dependent on the infrastructure spending boom from those positioned to benefit from what it has already created.

I’ll also reveal another healthcare company – name and ticker symbol – I believe is particularly well positioned to profit from this shift.

The presentation premieres Monday, November 23, at 10 a.m. ET.

Reserve your spot for Life After Nvidia here.

Nvidia has made fortunes selling the machinery of AI. I believe the next great fortunes will come from putting that machinery to work.

Regards,

Eric Fry

Senior Investment Analyst, InvestorPlace

P.S. Nvidia’s latest earnings may have been spectacular, but investors are already considering what Jensen Huang’s resignation means for the AI buildout a year from now. Good thing there’s a lot more to the AI Revolution than selling chips to data center builders. Eric believes the most interesting opportunities are emerging among businesses that can use AI to make better products, cut costs, and increase profits. And he’s found another healthcare stock that fits the bill. Eric will show us that company during his free Life After Nvidia presentation. Save your spot here.


Article printed from InvestorPlace Media, https://investorplace.com/market360/2026/11/the-ai-booms-next-winners-may-have-nothing-to-do-with-nvidia/.

©2026 InvestorPlace Media, LLC